Markets

Reported Sunday, Incyte's Minjuvi Plus Rituximab And Lenalidomide Now PBS-Funded In Australia, First New R/R Follicular Lymphoma Therapy Reimbursed In Nine Years

Aug 3, 2026 · 02:36 AM ET· updated 2h ago

MinjuvI (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen listed on the Pharmaceutical Benefits Scheme

Why It Matters

Incyte's cancer medicine got approval to be paid for by Australia's government health system. This is good news because it means more patients can access this treatment, and the company might earn more money from selling it there.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

INCY119.52

-3.47 (-2.82%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.